Business
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products f
About this update from Dyadic International, Inc.
[{"type":"image","alt":"Dyadic International, Inc.","displaySize":"","headline":null,"caption":"Dyadic International, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":180,"url":"https://media.zenfs.com/en/globenewswire.com/2a288e59b65031a67c22f5fb4925ffb4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PBlJ.1nJfXGJZqZFhMHG6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a288e59b65031a67c22f5fb4925ffb4","width":300,"height":180}},"lazy":false},{"type":"text","content":"JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products for use in serum-free cell culture media applications in the life science, food and nutrition markets.","length":605,"tagName":"p"},{"type":"text","content":"Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate market entry for Dyadic’s recombinant protein portfolio in cell culture media and related applications, while Dyadic retains the ability to sell directly and to work with additional partners globally.","length":395,"tagName":"p"},{"type":"text","content":"The collaboration is intended to accelerate the penetration of Dyadic’s recombinant protein products produced using its microbial expression platforms in industries including research, diagnostics, cultured meat and life sciences biomanufacturing that require reliable, scalable, and cost-effective sources of growth factors and functional proteins. Opes has already sampled multiple customers utilizing serum free cell culture media in life sciences, food and nutrition applications.","length":496,"tagName":"p"},{"type":"text","content":"“This collaboration supports our commercial objectives by extending our recombinant protein portfolio in target markets with a partner that has strong, existing s...